Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer: Results of a phase II study in elderly patients or patients with impaired performance status

摘要: Abstract Background Three-weekly docetaxel is active in patients with advanced esophagogastric cancer but myelosuppression may make this schedule unsuitable for some patient groups such as elderly, pretreated, or poor performance status patients. Patients and methods Eligible were chemonaive Karnofsky index ≤70% and/or had received prior platinum-based chemotherapy. Docetaxel 35 mg/m 2 was administered on days 1, 8, 15, 22, 29, 36 of a 49-day cycle. The primary endpoint disease stabilization rate. Results Of 46 (median age, 68.5 years; 47% ≥70 years) included, 87% ≤70 50% treatment. safety profile acceptable. Principal grade 3/4 toxicities leukopenia (9%) fatigue (14%). Fifteen experienced no progression ≥100 (disease rate: 36%). Overall response rate 9%; median overall survival 7.0 months. Conclusions Weekly well tolerated achieved one-third difficult-to-treat